A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1842 participants.
Also called NCT03495102
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,842 participants
- Sponsor
- Registry
-
NCT03495102 -
2017-003490-33
-
- Other papers using this trial's data
- Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study
- Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Austria, Canada, Greece, Hungary, Israel, Italy, Mexico, Poland, Puerto Rico, Romania, Russia, Slovakia, Spain, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT03495102. Randomized; double masking; primary purpose treatment. Start 2018-04-05 (actual); primary completion 2019-05-28 (actual). Results posted on 2020-06-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
- Acronym
- AWARD-11
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Dulaglutide
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03495102- Content hash
a37d891bcf08bca465a6b099d83c618a8b0c9422a189ca3e8d930bc495cc5026